Go Pro
NYSE:PFE

Pfizer Q2 2026 Earnings Report

Pfizer logo
$24.04 +0.32 (+1.34%)
Closing price 03:59 PM Eastern
Extended Trading
$24.08 +0.05 (+0.20%)
As of 07:48 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Pfizer EPS Results

Actual EPS
N/A
Consensus EPS
$0.68
Beat/Miss
N/A
One Year Ago EPS
N/A

Pfizer Revenue Results

Actual Revenue
N/A
Expected Revenue
$14.44 billion
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pfizer Announcement Details

Quarter
Q2 2026
Time
Before Market Opens
Conference Call Date
Tuesday, August 4, 2026
Conference Call Time
10:00AM ET

Conference Call Resources

Pfizer Earnings Headlines

Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
See More Pfizer Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pfizer? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pfizer and other key companies, straight to your email.

About Pfizer

Pfizer (NYSE:PFE) (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business. Notable products historically and in recent years have included established brands such as Lipitor and Viagra, specialty therapies like Xeljanz and Eliquis (developed and marketed in collaboration with Bristol-Myers Squibb), and vaccines including Prevnar. More recently, Pfizer partnered with BioNTech to develop the Comirnaty COVID-19 vaccine and developed the oral antiviral Paxlovid, reflecting the company’s capabilities across both biologics and small-molecule therapeutics.

Pfizer operates globally with research, manufacturing and commercial operations across North America, Europe, Asia and other regions, serving patients and healthcare systems worldwide. Its growth has been shaped by a series of strategic transactions and partnerships over decades, including major acquisitions that expanded its therapeutic breadth and capabilities. The company emphasizes external collaborations, in-licensing and acquisitions alongside internal R&D to build and sustain its product pipeline.

Leadership and organizational strategy center on sustained investment in research and development, regulatory engagement and global commercial execution. As a large, diversified biopharma, Pfizer balances near-term product commercialization with longer-term innovation efforts aimed at advancing new therapies and vaccines through clinical development and into clinical practice.

View Pfizer Profile